GSK agreed to acquire Nuvalent for $10.6 billion, a multi-asset deal aimed at strengthening GSK’s oncology pipeline with precision NSCLC therapies. Two programs are under FDA review—zidesamtinib for ROS1-mutant NSCLC and neladalkib for ALK-mutant disease—with FDA decision target dates later this year. The acquisition is also framed around addressing efficacy and tolerability gaps, including brain-penetrant activity to target CNS metastasis limitations. In a separate molecular glue partnership move, Novartis extended its collaboration with Orionis Biosciences with an additional $40 million upfront and up to $1.4 billion in milestones, reinforcing Novartis’ continued investment in targeted protein degradation and molecular glue approaches as it expands oncology-related discovery programs.